Objective To explore the method for differentiation induction of leukemia cells into dendritic cells(DC) by A23187 in vitro. Methods Chronic myeloid leukemia K562 cells were cultured with A23187 or cytokine to induce differentiation and form DC. The morphologic features of cells were observed under inverted microscope, the changes of DC surface marks were determined by flow cytometry and RT-PCR, the ability to stimulate lymphocyte proliferation was tested by MTT colorimetry. Results Under the condition of the does (385 ng/ml) of A23187 for four days, some of K562 cells were found in typical dendritic appearance.The expression of DC markers CD1a,CD83 ,HLA-DR,CD86 and CD80 was 6.65 ±2.70,7.37 ±2.40,6.24 ±4.29, 21.60 ± 3.84, 18.52 ± 4.48 repectively, and increased obviously compared with the negative control group(2.80 ±0.52,1.85 ±0.56,2.25 ±0.47,6.69 ±0.83,9.96 ±3.53). The differences had statistical significance (P < 0.05). K562 cells derived from DC acquired the ability to stimulate lymphocyte proliferation.Conclusion A23187 can induce the leukemia cells differenntiation into activated DC-like cells rapidly.

RNAi is a process of effective gene silencing. Human papillomaviruses 16 (HPV16), as the most prevalent genotype of cervical cancer, encodes the E6 and E7 oncogenes, which is pivotal for maintenance of malignant phenotypes. Recently, some significant advances have been obtained in RNA interfering effect on HPV16 E6/E7. In vitro, it has been developed more effective vector systems and screened for more specific targeted sequences. In vivo, the corresponding animal models have been established, which lay a good foundation for the clinical research.

Early detection of HCC is critical for a good prognosis. Therefore, the development of tumor markers that can detect HCC at even earlier stages is urgent. Recent researches show that the human cervical cancer oncogene, gamma-glutamyl transferase mRNA, human telomerase reverse transcriptase mRNA, the proteins such as glypican-3, golgi protein 73, vascular endothelial growth factor and transforming growth factor-β1 could serve as markers for early detection of HCC.

Familial pancreatic cancer is a known hereditary cancer syndrome with autosomal dominant inheritance and accounts for about 3% of all pancreatic cancers. With the development of molecular genetics,several genes have been identified related with the familial pancreatic cancer, including breast cancer susceptibility gene 2, Palladin, cyclin-dependent kinase inhibitor 2A, et al. In particular, mutations in some of these genes have been defined as the hereditary basis of particular cancer syndromes. Molecular genetics surveillance for high risk populace can lead to the diagnosis of asymptomatic, early-stage pancreatic cancer or precancerous lesions.

S-1 is an upgraded product of tegafur and UFT. Compared with 5-FU, it has stronger anticancer activity, and relative rare gastrointestinal adverse reaction. Many clinical studies have demonstrated S-1 has very good efficacy and safety in patients with advanced gastric cancer. The efficacy of single S-1 has been approved better than other available anti-cancer drugs in the treatment of gastric cancer, and similar to combination regimens such as cisplatin plus fluorouracil.

With the deep study of the molecular biology mechanism during esophageal carcinoma development, there are major progressions in the study of chemotherapy related genes and proteins in esophageal carcinoma, including EGFR, p53, ERCC1, MRP and P-gp, and the measurements of these genes and protein benefit the prediction of chemotherapy sensitivity and making the individualized treatment protocols.

The development of the minimally invasive targeted ablation tendency creates a new therapy for lung cancer. This treatment is featured with considerably extensive indication ,excellent local control and survival time, low incidence and controllable complications. There are many strong proofs of clinical efficacy and safety in this field presently.

With the development of phamacogenomic and molecular biology, it has been revealed that the curative effect of non-small-cell lung cancer (NSCLC) is closely related to tumor molecular markers. Predictive biomarkers in NSCLC patients, including ERCC1, BRCA1, hMLH1, hMSH2, RRM1, β-tubulin, TS,EGFR and K-ras, can predict individual patient's response to chemotherapy or targeted therapy, making individualized therapy be possible.

Chemokines are a group of small molecules that cause the directed migration of cells. In lung cancer, chemokines involve in the regulation of tumor cell growth, angiogenesis, anti-tumor immunity and remote metastasis, which provides a novel therapeutic target for lung cancer.

With a view to patterns of local recurrence after breast conserving surgery, whole breast irradiation(WBI) after surgery is controversial and partial-breast irradiation(PBI) came up. Many clinical trials related with accelerated partial-breast irradiation using a variety of radiotherapeutic techniques such as interstitial brachytherapy (IBT), MammoSite Radiation Therapy System, intraoperative radiotherapy(IORT), threedimensional conformal radiotherapy(3-DCRT)and intensity modulated radiation therapy(IMRT) in selected patients have been carried out. Accelerated partial-breast irradiation that provides faster, more convenient treat-ment demonstrates local control rate and safety comparable to that of whole breast irradiation. Partial breast irradiation may be an alternative way to whole breast radiotherapy and will be one of the standard treatments in women with early breast cancer seeking breast conservation.